Targeting the MDM2-p53 axis could give us positive results in the search for new therapies: the construction of a mutant p53 protein with substitution of amino acid residues avoiding its ubiquitination inhibited glioma cell proliferation in vitro [62]. This evidence concerns the gene MDM2 and glioma.